|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCL26 |
Gene summary for CCL26 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCL26 | Gene ID | 10344 |
| Gene name | C-C motif chemokine ligand 26 | |
| Gene Alias | IMAC | |
| Cytomap | 7q11.23 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9Y258 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10344 | CCL26 | P4T-E | Human | Esophagus | ESCC | 2.70e-29 | 1.80e+00 | 0.1323 |
| 10344 | CCL26 | P5T-E | Human | Esophagus | ESCC | 1.31e-19 | 1.32e+00 | 0.1327 |
| 10344 | CCL26 | P9T-E | Human | Esophagus | ESCC | 2.74e-25 | 9.98e-01 | 0.1131 |
| 10344 | CCL26 | P12T-E | Human | Esophagus | ESCC | 1.31e-07 | 6.94e-01 | 0.1122 |
| 10344 | CCL26 | P15T-E | Human | Esophagus | ESCC | 1.21e-12 | 7.20e-01 | 0.1149 |
| 10344 | CCL26 | P22T-E | Human | Esophagus | ESCC | 2.68e-26 | 1.33e+00 | 0.1236 |
| 10344 | CCL26 | P26T-E | Human | Esophagus | ESCC | 9.93e-05 | 3.46e-01 | 0.1276 |
| 10344 | CCL26 | P27T-E | Human | Esophagus | ESCC | 1.20e-15 | 1.28e+00 | 0.1055 |
| 10344 | CCL26 | P28T-E | Human | Esophagus | ESCC | 9.14e-22 | 1.32e+00 | 0.1149 |
| 10344 | CCL26 | P30T-E | Human | Esophagus | ESCC | 2.24e-10 | 8.95e-01 | 0.137 |
| 10344 | CCL26 | P31T-E | Human | Esophagus | ESCC | 1.85e-55 | 1.75e+00 | 0.1251 |
| 10344 | CCL26 | P32T-E | Human | Esophagus | ESCC | 7.30e-10 | 7.00e-01 | 0.1666 |
| 10344 | CCL26 | P40T-E | Human | Esophagus | ESCC | 6.27e-06 | 4.57e-01 | 0.109 |
| 10344 | CCL26 | P49T-E | Human | Esophagus | ESCC | 1.41e-02 | 1.46e+00 | 0.1768 |
| 10344 | CCL26 | P52T-E | Human | Esophagus | ESCC | 1.61e-05 | 7.42e-01 | 0.1555 |
| 10344 | CCL26 | P54T-E | Human | Esophagus | ESCC | 5.49e-03 | 9.13e-01 | 0.0975 |
| 10344 | CCL26 | P74T-E | Human | Esophagus | ESCC | 6.62e-21 | 2.40e+00 | 0.1479 |
| 10344 | CCL26 | P75T-E | Human | Esophagus | ESCC | 2.78e-08 | 1.10e+00 | 0.1125 |
| 10344 | CCL26 | P83T-E | Human | Esophagus | ESCC | 1.01e-06 | 4.81e-01 | 0.1738 |
| 10344 | CCL26 | P107T-E | Human | Esophagus | ESCC | 7.36e-06 | 4.52e-01 | 0.171 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00713473 | Oral cavity | OSCC | cellular response to interleukin-1 | 58/7305 | 113/18723 | 5.14e-03 | 2.01e-02 | 58 |
| GO:00509204 | Oral cavity | OSCC | regulation of chemotaxis | 105/7305 | 223/18723 | 8.27e-03 | 3.01e-02 | 105 |
| GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
| GO:00703716 | Oral cavity | OSCC | ERK1 and ERK2 cascade | 150/7305 | 330/18723 | 9.47e-03 | 3.38e-02 | 150 |
| GO:007162110 | Oral cavity | OSCC | granulocyte chemotaxis | 62/7305 | 125/18723 | 1.02e-02 | 3.52e-02 | 62 |
| GO:00703724 | Oral cavity | OSCC | regulation of ERK1 and ERK2 cascade | 140/7305 | 309/18723 | 1.34e-02 | 4.46e-02 | 140 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| CCL26 | ACKR2 | CCL26_ACKR2 | CCL | HNSCC | OSCC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCL26 | SNV | Missense_Mutation | novel | c.80G>A | p.Ser27Asn | p.S27N | Q9Y258 | protein_coding | deleterious(0.04) | benign(0.069) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CCL26 | SNV | Missense_Mutation | novel | c.280T>G | p.Leu94Val | p.L94V | Q9Y258 | protein_coding | deleterious(0.01) | benign(0.225) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| CCL26 | SNV | Missense_Mutation | c.34N>A | p.Leu12Met | p.L12M | Q9Y258 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCL26 | SNV | Missense_Mutation | novel | c.279N>C | p.Gln93His | p.Q93H | Q9Y258 | protein_coding | tolerated(0.37) | benign(0.057) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| CCL26 | SNV | Missense_Mutation | novel | c.92N>G | p.Lys31Arg | p.K31R | Q9Y258 | protein_coding | tolerated(0.18) | benign(0.115) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCL26 | insertion | Frame_Shift_Ins | novel | c.124_125insA | p.Leu42HisfsTer10 | p.L42Hfs*10 | Q9Y258 | protein_coding | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | ||
| CCL26 | SNV | Missense_Mutation | c.158C>G | p.Thr53Ser | p.T53S | Q9Y258 | protein_coding | deleterious(0.05) | probably_damaging(0.946) | TCGA-22-5485-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |